Probiotic Composition for Alcohol and Acetaldehyde Degradation
Summary
The European Patent Office published patent application EP3415155A1 for Cell Biotech Co., Ltd., covering a probiotic composition designed to degrade alcohol and acetaldehyde in the body. The patent identifies specific bacterial strains including Lactobacillus and Bifidobacterium species classified under multiple A61K compositions. The patent designates 33 European states including Germany, France, UK, Italy, and Spain.
What changed
The European Patent Office granted patent EP3415155A1 to Cell Biotech Co., Ltd. for a probiotic composition comprising specific bacterial strains capable of degrading alcohol and acetaldehyde. The composition includes bacterial strains classified under A61K 35/744, 35/745, and 35/747 categories, with additional coverage under A61P 1/16 (liver disorders) and A61P 25/32 (substance dependence). The patent application was published with kind code A1, indicating a European patent application with search report.
For pharmaceutical and nutraceutical manufacturers developing alcohol metabolism or liver support products, this patent establishes intellectual property barriers for probiotic-based approaches. Competitors seeking similar compositions should evaluate design-around options or licensing opportunities. Healthcare providers and consumers should be aware that proprietary probiotic formulations for alcohol degradation now exist under European patent protection.
What to do next
- Monitor for updates
Archived snapshot
Apr 8, 2026GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.
COMPOSITION FOR ALCOHOL OR ACETALDEHYDE DEGRADATION COMPRISING PROBIOTICS
Publication EP3415155A1 Kind: A1 Apr 01, 2026
Applicants
Cell Biotech Co., Ltd.
Inventors
CHUNG, Myung Jun
IPC Classifications
A61P 35/00 20060101AFI20260224BHEP A61P 43/00 20060101ALI20260224BHEP A61P 1/16 20060101ALI20260224BHEP A61K 35/744 20150101ALI20260224BHEP A61K 35/745 20150101ALI20260224BHEP A61K 35/747 20150101ALI20260224BHEP A61K 36/28 20060101ALI20260224BHEP A61K 36/484 20060101ALI20260224BHEP C12N 1/20 20060101ALI20260224BHEP A23L 33/135 20160101ALI20260224BHEP A61P 25/32 20060101ALI20260224BHEP
Designated States
AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR
Related changes
Get daily alerts for ChangeBridge: EPO Bulletin - Therapeutics (A61P)
Daily digest delivered to your inbox.
Free. Unsubscribe anytime.
Source
About this page
Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission
Source document text, dates, docket IDs, and authority are extracted directly from EPO.
The plain-English summary, classification, and "what to do next" steps are AI-generated from the original text. Cite the source document, not the AI analysis.
Classification
Who this affects
Taxonomy
Browse Categories
Get alerts for this source
We'll email you when ChangeBridge: EPO Bulletin - Therapeutics (A61P) publishes new changes.